Lignes directrices pour un consensus international dans la gestion de la Myasthénie

Rubrique ouverte à tous en lecture seule.
POUR ACCEDER AUX NOMBREUX AUTRES FORUMS IL EST NECESSAIRE DE S'INSCRIRE (fonction M'enregistrer en haut à droite de l'écran).
Répondre
Avatar de l’utilisateur

Auteur du sujet
Pboulanger
Administrateur
Administrateur
Messages : 4692
Inscription : 02 févr. 2010 18:41
Localisation : La Chapelle en Serval F-60520
    Windows 8.1 Firefox
Genre :
Résidence : France
Zodiaque : Lion
Âge : 60
Contact :

Lignes directrices pour un consensus international dans la gestion de la Myasthénie

Message par Pboulanger » 01 juil. 2016 10:13

:hi:

Lu sur http://www.ncbi.nlm.nih.gov/pubmed/27358333
Traduction disponible directement en cliquant en bas à droite de ce message sur notre forum
Image
1. Neurology. 2016 Jun 29. pii: 10.1212/WNL.0000000000002790. [Epub ahead of print]

International consensus guidance for management of myasthenia gravis: Executive
summary.


Sanders DB(1), Wolfe GI(2), Benatar M(2), Evoli A(2), Gilhus NE(2), Illa I(2),
Kuntz N(2), Massey JM(2), Melms A(2), Murai H(2), Nicolle M(2), Palace J(2),
Richman DP(2), Verschuuren J(2), Narayanaswami P(2).


  • OBJECTIVE:
    To develop formal consensus-based guidance for the management of myasthenia gravis (MG).
  • METHODS:
    In October 2013, the Myasthenia Gravis Foundation of America appointed a Task Force to develop treatment guidance for MG, and a panel of 15 international experts was convened.
    The RAND/UCLA appropriateness methodology was used to develop consensus guidance statements. Definitions were developed for goals of treatment, minimal manifestations, remission, ocular MG, impending crisis, crisis, and refractory MG.
    An in-person panel meeting then determined 7 treatment topics to be addressed. Initial guidance statements were developed from literature summaries.
    Three rounds of anonymous e-mail votes were used to attain consensus on guidance statements modified on the basis of panel input.
  • RESULTS:
    Guidance statements were developed for symptomatic and immunosuppressive treatments, IV immunoglobulin and plasma exchange, management of impending and manifest myasthenic crisis, thymectomy, juvenile MG, MG associated with antibodies to muscle-specific tyrosine kinase, and MG in pregnancy.
  • CONCLUSION:
    This is an international formal consensus of MG experts intended to be a guide for clinicians caring for patients with MG worldwide.
© 2016 American Academy of Neurology.

DOI: 10.1212/WNL.0000000000002790
PMID: 27358333 [PubMed - as supplied by publisher]



Amicalement,
Image

Répondre

Revenir vers « Informations »

Qui est en ligne ?

Utilisateurs parcourant ce forum : Aucun utilisateur inscrit et 0 invité